PDCD1 and non-small cell lung carcinoma: Preclinical findings and evidence from NSCLC tissue suggest that PD-L1 and IDO represent distinct, nonoverlapping routes to immune evasion and highlight their combined targeting using anti-PD-1/PD-L1 and anti-IDO inhibitors as a promising therapeutic strategy [11,12,13,14].